Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
<br><strong>Background<br></strong> Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZenec...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2021
|
| _version_ | 1826299717946966016 |
|---|---|
| author | Stuart, ASV Shaw, RH Liu, X Greenland, M Aley, PK Andrews, NJ Cameron, JC Charlton, S Clutterbuck, EA Collins, AM Darton, T Dinesh, T Duncan, CJA England, A Faust, SN Ferreira, DM Finn, A Goodman, AL Green, CA Hallis, B Heath, PT Hill, H Horsington, BM Lambe, T Lazarus, R Libri, V Lillie, PJ Mujadidi, YF Payne, R Plested, EL Provstgaard-Morys, S Ramasamy, MN Ramsay, M Read, RC Robinson, H Screaton, GR Singh, N Turner, DPJ Turner, PJ Vichos, I White, R Nguyen-Van-Tam, JS Snape, MD |
| author2 | Com-COV2 Study Group |
| author_facet | Com-COV2 Study Group Stuart, ASV Shaw, RH Liu, X Greenland, M Aley, PK Andrews, NJ Cameron, JC Charlton, S Clutterbuck, EA Collins, AM Darton, T Dinesh, T Duncan, CJA England, A Faust, SN Ferreira, DM Finn, A Goodman, AL Green, CA Hallis, B Heath, PT Hill, H Horsington, BM Lambe, T Lazarus, R Libri, V Lillie, PJ Mujadidi, YF Payne, R Plested, EL Provstgaard-Morys, S Ramasamy, MN Ramsay, M Read, RC Robinson, H Screaton, GR Singh, N Turner, DPJ Turner, PJ Vichos, I White, R Nguyen-Van-Tam, JS Snape, MD |
| author_sort | Stuart, ASV |
| collection | OXFORD |
| description | <br><strong>Background<br></strong>
Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer–BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).
<br><strong>Methods<br></strong>
Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8–12 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311.
<br><strong>Findings<br></strong>
Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation.
<br><strong>Interpretation<br></strong>
Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.
<br><strong>Funding<br></strong>
UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use in the trial by Novavax. |
| first_indexed | 2024-03-07T05:06:13Z |
| format | Journal article |
| id | oxford-uuid:da01cb4e-98ba-4417-b888-9832a907d5fe |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:06:13Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:da01cb4e-98ba-4417-b888-9832a907d5fe2022-03-27T09:00:18ZImmunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:da01cb4e-98ba-4417-b888-9832a907d5feEnglishSymplectic ElementsElsevier2021Stuart, ASVShaw, RHLiu, XGreenland, MAley, PKAndrews, NJCameron, JCCharlton, SClutterbuck, EACollins, AMDarton, TDinesh, TDuncan, CJAEngland, AFaust, SNFerreira, DMFinn, AGoodman, ALGreen, CAHallis, BHeath, PTHill, HHorsington, BMLambe, TLazarus, RLibri, VLillie, PJMujadidi, YFPayne, RPlested, ELProvstgaard-Morys, SRamasamy, MNRamsay, MRead, RCRobinson, HScreaton, GRSingh, NTurner, DPJTurner, PJVichos, IWhite, RNguyen-Van-Tam, JSSnape, MDCom-COV2 Study Group<br><strong>Background<br></strong> Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer–BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax). <br><strong>Methods<br></strong> Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8–12 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311. <br><strong>Findings<br></strong> Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation. <br><strong>Interpretation<br></strong> Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification. <br><strong>Funding<br></strong> UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use in the trial by Novavax. |
| spellingShingle | Stuart, ASV Shaw, RH Liu, X Greenland, M Aley, PK Andrews, NJ Cameron, JC Charlton, S Clutterbuck, EA Collins, AM Darton, T Dinesh, T Duncan, CJA England, A Faust, SN Ferreira, DM Finn, A Goodman, AL Green, CA Hallis, B Heath, PT Hill, H Horsington, BM Lambe, T Lazarus, R Libri, V Lillie, PJ Mujadidi, YF Payne, R Plested, EL Provstgaard-Morys, S Ramasamy, MN Ramsay, M Read, RC Robinson, H Screaton, GR Singh, N Turner, DPJ Turner, PJ Vichos, I White, R Nguyen-Van-Tam, JS Snape, MD Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial |
| title | Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial |
| title_full | Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial |
| title_fullStr | Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial |
| title_full_unstemmed | Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial |
| title_short | Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial |
| title_sort | immunogenicity safety and reactogenicity of heterologous covid 19 primary vaccination incorporating mrna viral vector and protein adjuvant vaccines in the uk com cov2 a single blind randomised phase 2 non inferiority trial |
| work_keys_str_mv | AT stuartasv immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT shawrh immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT liux immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT greenlandm immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT aleypk immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT andrewsnj immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT cameronjc immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT charltons immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT clutterbuckea immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT collinsam immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT dartont immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT dinesht immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT duncancja immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT englanda immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT faustsn immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT ferreiradm immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT finna immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT goodmanal immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT greenca immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT hallisb immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT heathpt immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT hillh immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT horsingtonbm immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT lambet immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT lazarusr immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT libriv immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT lilliepj immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT mujadidiyf immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT payner immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT plestedel immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT provstgaardmoryss immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT ramasamymn immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT ramsaym immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT readrc immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT robinsonh immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT screatongr immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT singhn immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT turnerdpj immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT turnerpj immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT vichosi immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT whiter immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT nguyenvantamjs immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial AT snapemd immunogenicitysafetyandreactogenicityofheterologouscovid19primaryvaccinationincorporatingmrnaviralvectorandproteinadjuvantvaccinesintheukcomcov2asingleblindrandomisedphase2noninferioritytrial |